Treating prostate cancer with immunotherapy remains challenging. However, researchers at City of Hope have developed a chimeric antigen receptor (CAR) T cell (CAR-T) therapy, and the initial results of the first-in-human PhaseRead More…
Activated T cells with certain surface markers, such as checkpoint inhibitor proteins, are regulated by another type of immune system cell—natural killer (NK) cells. In this way, the body likely suppresses destructiveRead More…
Acute myeloid leukemia (AML) is an aggressive blood cancer caused by a plethora of genetic mutations acquired throughout one’s lifetime. One of these genes, the tumor suppressor gene TP53, plays a crucialRead More…
In a recent study, researchers from the University of Texas MD Anderson Cancer Center in the United States reported favorable results from a Phase I/II clinical trial involving 37 patients with relapsedRead More…
In a recent study, researchers from Stanford University in the United States collected data from previous studies on CAR-T cell therapy to investigate the reactivation of human herpesvirus 6 (HHV-6) in patientsRead More…
In recent years, scientists have harnessed the power of gene editing technology to reprogram immune cells into therapies capable of targeting cancer. However, these immunotherapies are not universally effective across all patientsRead More…
Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive brain tumor that usually occurs in children between 5 and 7. This fast-growing tumor forms in the part of a child’s brain responsible forRead More…
In a recent study, researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), the Weizmann Institute of Science in Israel, the University of South Florida, and the University of Texas MDRead More…
Since the world’s first chimeric antigen receptor (CAR)-T cell therapy was approved for marketing in 2017, the Food and Drug Administration (FDA) has approved a total of six CAR-T cell therapies toRead More…
PIn a new study, Spanish researchers have developed a cell therapy for a type of leukemia for which there are currently few treatment options. This STAb-T cell therapy is based on STAb-TRead More…